Optimal Anemia Treatment in End Stage Renal Disease (ERSD)

NCT02273570 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Hyperparathyroidism, Secondary

Interventions

DRUG: standard care
DRUG: Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D

Sponsor

Azienda Ospedaliera Sant'Anna

Collaborators

[object Object]